Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 12/12/25 → 12/12/27 |
Financiación
- Bristol Myers Squibb Company: 25.000,00 US$
25-GU-91-BMS (CA2440012): A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy for Metastatic Urothelial Cancer in Participants with Disease Progression on or After an Immunotherapy-Based Treatment
- Myint, Zin (PI)